HF 4852Session 2025-2026
Formulary Committee members with a potential conflict of interest permitted to participate in committee communications and discussions, commissioner of human services required to develop a public comment process for recommendations, and committee required to seek expertise from the Minnesota Rare Disease Advisory Council.
Progress
- Introduced
- In committee
- Passed one chamber Not yet
- Passed legislature Not yet
- Sent to governor Not yet
- Became law Not yet
Legislative history
-
House
Introduction and first reading, referred to Health Finance and Policy